Floatz logo

CASPOFUNGIN

Leukemia

European Organisation for Research and Treatment of Cancer - EORTCSmall moleculePhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

View all 50

Same molecule, other indications

CASPOFUNGIN is also rated in:

fungal infectious diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
acute monocytic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →